Professor of Medicine, Head of the Department of Thoracic Oncology at Bichat Hospital in Paris (Paris-Diderot University). Dr. Gérard Zalcman is a member of the INSERM U830 laboratory, « Genetics & Biology of Cancers », at the Institut Curie Research Center.
Conseil scientifique
Jean-Louis Junien
Chairman of the Scientific Advisory Board and former member of the Board of Directors of Inventiva. Jean-Louis Junien is a senior executive with extensive experience in the pharmaceutical industry.
Manal Abdelmalek, MD
Professor of Medicine in the Department of Gastroenterology and Hepatology at Duke University and Director of the NAFLD Clinical Research Program at Duke University. Dr. Manal Abdelmalek is a permanent member of the NASH Clinical Research Network (NASH CRN).
Dr. Glen Clack
Honorary Professor of Translational Medicine in the Department of Oncology and Metabolism at the University of Sheffield and former Senior Medical Director of the Translational Medicine in Oncology Unit at Astra Zeneca.
Kenneth Cusi, MD
Professor Kenneth Cusi, Chief of the Department of Inkiness, Diabetes & Metabolism in the Department of Medicine at the University of Florida in Gainesville. His research focuses on the fields of endocrinology, diabetes and metabolism in adults, both clinical and basic research. Dr. Cusi is interested in the role of obesity and lipotoxicity in the development of type 2 diabetes and its complications, with a particular focus on the pathogenesis of NAFLD.
Sven Frankish, MD
Professor of Medicine at the Faculty of Medicine and Life Sciences of the University of Antwerp and Chairman of the Department of Gastroenterology and Hepatology. His research unit focuses on the pathophysiological mechanisms of NASH.
Arun J. Sanyal, MD
Professor of Medicine, Physiology and Molecular Pathology in the Department of Gastroenterology at the Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia (USA). Dr. Sanyal is also Chair of the National Institutes of Health (NIH) NASH Clinical Research Network, the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Consortium, and the Liver Forum for NASH and Fibrosis. His research focuses on all aspects of NAFLD and NASH, as well as complications of cirrhosis and end-stage liver disease.
Andrew Shenker, MD
Expert in rare diseases and gene therapies. Dr. Andrew Shenker is a pediatric physician with over 20 years of experience in academia, biotech and the pharmaceutical industry. Most recently, he is Vice-President at GlaxoSmithKline Rare Diseases. He has expertise in cell signaling and disease pathophysiology, clinical pharmacology, biomarker strategy implementation and clinical development of novel treatments for rare metabolic and neurological diseases, including lysosomal storage diseases.
Gerard Zalcman, MD
Elisabetta Bugianesi, MD
Professor of Gastroenterology and Scientific Director of the Department of Medical Sciences of the University of Turin in Italy. His research focuses on the pathophysiological mechanisms of NASH, the natural history of the disease including hepatocarcinoma and the development of non-invasive markers of fibrosis.
Trever Bivona, MD, PhD
Professor of Medicine and Cellular and Molecular Pharmacology at UCSF, Helen Diller Family Comprehensive Cancer Center and Principal Investigator at Chan-Zuckerberg Biohub. Dr. Bivona’s research team focuses on understanding the main signal transduction pathways and molecular characteristics behind cancer growth, evolution and resistance to therapies.
